Psoriatic Arthritis Treatment Update

About 30% of patients with psoriasis have psoriatic arthritis (PsA), a complex, multi-faceted, chronic, inflammatory musculoskeletal and skin disease for which the treatment has changed considerably over the past few years.1 Biosimilars and other new drugs have become a therapeutic turning point for many patients suffering from rheumatic illnesses, including PsA. The treatment of PsA... [Read More]
Source: The Rheumatologist - Category: Rheumatology Authors: Tags: Conditions Drug Updates Guidelines PsA Resource Center Psoriatic Arthritis Source Type: research

Related Links:

SPRING HOUSE, PENNSYLVANIA, December 3, 2021 – The Janssen Pharmaceutical Companies of Johnson &Johnson today announced new TREMFYA® (guselkumab) efficacy and safety data from the Phase 3b COSMOS trial published in Annals of the Rheumatic Diseases (ARD), evaluating this selective interleukin (IL)-23 inhibitor in adults with active psoriatic arthritis (PsA) who demonstrated inadequate efficacy or intolerance to tumor necrosis factor inhibition (TNFi).1 Results showed significantly higher proportions of patients treated with TREMFYA had improvement in joint signs and symptoms and complete skin clearance versus ...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
Med Sci Monit. 2021 Dec 2;27:e934927. doi: 10.12659/MSM.934927.ABSTRACTBACKGROUND Psoriasis is a chronic, immune-mediated and hyperproliferative skin disease with both genetic and environmental components. Copy number variations (CNV) of IL22 and LCE3C-LCE3B deletion have been confirmed to be predisposed to psoriasis vulgaris (PsV) in several ethnic groups. However, it remains to be clarified whether CNVs of IL22 and LCE3C are associated with different subtypes of psoriasis (psoriatic arthritis, PsA; erythrodermic psoriasis, EP; and generalized pustular psoriasis, GPP). MATERIAL AND METHODS We enrolled 897 Han Chinese indi...
Source: Medical Science Monitor - Category: Research Authors: Source Type: research
Conclusion: Specific PASI thresholds were not well suited to predict elevated biomarkers of systemic inflammation and cardiovascular risk on an individual patient level. Therefore, PASI, and possibly other purely cutaneous measures, may not be ideal as stand-alone parameters to define disease severity and eligibility for systemic treatment. Our results are relevant for the ongoing discussion on the definition of psoriasis severity and eligibility for systemic treatment. Further research addressing the added value of a set of biomarkers of systemic inflammation in the assessment of psoriasis severity would be desirable.Dermatology
Source: Dermatology - Category: Dermatology Source Type: research
Expert Rev Clin Immunol. 2021 Nov 30. doi: 10.1080/1744666X.2022.2011720. Online ahead of print.ABSTRACTINTRODUCTION: Psoriasis is a chronic immune-mediated disease affecting 125 million people globally. It is characterized by erythematous plaques in the skin, covered by silvery scales. However, non-cutaneous manifestations (e.g., joint symptoms in psoriatic arthritis) and a high prevalence of other immune-mediated diseases such as inflammatory bowel diseases reflect its systemic nature. So far, research on psoriasis pathogenesis has improved our knowledge of the roles of the immune system, and cytokines play significant r...
Source: Expert Review of Clinical Immunology - Category: Allergy & Immunology Authors: Source Type: research
CONCLUSIONS: The current review has provided some practical advice on how to manage psoriasis in a holistic manner. Somatology training institutions should consider incorporating Pso Well training in their program, thereby keeping abreast of new developments associated with psoriasis management. MBCT could be added to the set of holistic interventions for patients suffering from psoriasis, particularly those who suffer from poor psychological well-being. Robust clinical tests should be performed to evaluate the effectiveness of treatments, such as integrative patient management between the two professions.PMID:34847070
Source: Alternative Therapies in Health and Medicine - Category: Complementary Medicine Authors: Source Type: research
Expert Rev Clin Immunol. 2021 Nov 30. doi: 10.1080/1744666X.2022.2011720. Online ahead of print.ABSTRACTINTRODUCTION: Psoriasis is a chronic immune-mediated disease affecting 125 million people globally. It is characterized by erythematous plaques in the skin, covered by silvery scales. However, non-cutaneous manifestations (e.g., joint symptoms in psoriatic arthritis) and a high prevalence of other immune-mediated diseases such as inflammatory bowel diseases reflect its systemic nature. So far, research on psoriasis pathogenesis has improved our knowledge of the roles of the immune system, and cytokines play significant r...
Source: Expert Review of Clinical Immunology - Category: Allergy & Immunology Authors: Source Type: research
Immunol Res. 2021 Nov 25. doi: 10.1007/s12026-021-09251-y. Online ahead of print.ABSTRACTThe anthocyanidin delphinidin reduces psoriasiform lesions and inflammatory mediators in human cell culture systems. Its role in psoriatic disease has not yet been investigated. We assessed delphinidin's in vitro immunomodulatory effect on ex vivo stimulated peripheral blood mononuclear cells (PBMCs) from 50 individuals [26 with psoriasis, 10 with psoriatic arthritis (PsA) and 14 healthy controls (HCs)]. Cells were either left untreated or stimulated with PMA plus ionomycin in the presence or absence of delphinidin. Intracellular produ...
Source: Cell Research - Category: Cytology Authors: Source Type: research
Conclusions: Treatment with brodalumab rapidly results in high levels of complete and sustained skin clearance and greater cumulative treatment benefit in patients with moderate-to-severe psoriasis versus ustekinumab, regardless of concomitant PsA status.Dermatology
Source: Dermatology - Category: Dermatology Source Type: research
AbstractThe anthocyanidin delphinidin reduces psoriasiform lesions and inflammatory mediators in human cell culture systems. Its role in psoriatic disease has not yet been investigated. We assessed delphinidin ’s in vitro immunomodulatory effect on ex vivo stimulated peripheral blood mononuclear cells (PBMCs) from 50 individuals [26 with psoriasis, 10 with psoriatic arthritis (PsA) and 14 healthy controls (HCs)]. Cells were either left untreated or stimulated with PMA plus ionomycin in the presence or a bsence of delphinidin. Intracellular production of interferon-γ (IFNγ), interleukin-17A (IL-17A), and i...
Source: Immunologic Research - Category: Allergy & Immunology Source Type: research
Australas J Dermatol. 2021 Nov 23. doi: 10.1111/ajd.13752. Online ahead of print.ABSTRACTFor patients who do not achieve adequate disease control on biologic monotherapy, or monotherapy with an oral-systemic agent such as methotrexate, combination biologic therapy may be considered. To the best of our knowledge, we report the first case assessing the safety and efficacy of the combination of an interleukin-23 (IL-23) inhibitor (risankizumab) with a tumour necrosis factor-α (TNF-α) inhibitor (golimumab) in the treatment of psoriasis and psoriatic arthritis. After twelve months of treatment with risankizumab and ...
Source: The Australasian Journal of Dermatology - Category: Dermatology Authors: Source Type: research
More News: Arthritis | Psoriasis | Psoriatic Arthritis | Rheumatology | Skin